Federica De Galitiis

Cemiplimab in cutaneous squamous cell carcinoma: a longer follow‐up study focusing on the late toxicities

Summary Background and Objectives Cemiplimab was the first systemic therapy approved for advanced cutaneous squamous cell carcinoma (cSCC). Patients and Methods We report findings from the Italian early access program cohort, comprising 134 patients treated with cemiplimab, with...

Genetic characterization of suspected hereditary melanoma in a Central Italy cohort

Approximately 5–12% of cutaneous melanomas arise in a familial context, suggesting hereditary predisposition. Our analysis aims to investigate the clinical and genetic background of melanoma patients living in the Lazio area with a personal and/or family history of melanoma or ot...